Background: Rheumatoid arthritis (RA) flares remain poorly understood at a mechanistic level and have been difficult to study because of their sporadic nature. BIO-FLARE (BIOlogical Factors that Limit ...

Background The SELENA flare index (SFI) has functioned well in clinical and clinical trial settings (1), but has the limitation that it classifies only severe versus combined mild/moderate flares.

Objectives To evaluate the incidence of infection in patients with active rheumatoid arthritis (RA) treated with baricitinib, an oral selective Janus kinase (JAK)1 and JAK2 inhibitor. Methods ...

Objective To examine the fracture risk with use of disease-modifying antirheumatic drugs (DMARDs), statins, proton pump inhibitors (PPIs), opioids, non-opioid analgesics and psychotropic medications ...

Correspondence to Dr Antonis Fanouriakis, Rheumatology and Clinical Immunology Unit, “Attikon” University Hospital, Athens 12462, Greece; afanour{at}med.uoa.gr Our objective was to update the EULAR ...

Objective Randomised trials of type I anti-CD20 antibodies rituximab and ocrelizumab failed to show benefit in proliferative lupus nephritis (LN). We compared obinutuzumab, a humanised type II ...

Correspondence to Dr Peter Kvacskay, Department of Internal Medicine V Hematology Oncology Rheumatology, University Hospital Heidelberg, Heidelberg 69120, Germany; peter.kvacskay{at}med.uni-heidelberg ...

Department of Internal Medicine, Division of Rheumatology, University of Maastricht, Maastricht, The Netherlands Correspondence to: Professor D van der Heijde Department of Internal Medicine, Division ...

Dr S M Wong, Department of Medicine, Prince of Wales Hospital, 30–32 Ngan Shing Street, Shatin, New Territories, Hong Kong, Special Administrative Region China A range of options are available for the ...

Objective: To evaluate the efficacy and safety of adding sulfasalazine to leflunomide treatment compared with switching to sulfasalazine alone in patients with RA with an inadequate response to ...

Background Dermatomyositis (DM) is a rare, multi-system idiopathic inflammatory myopathy characterized by skin rash and muscle weakness that is often accompanied by pain and fatigue. Other ...

Correspondence to Professor Sergey Moiseev, Tareev Clinic of Internal Diseases, Sechenov First Moscow State Medical University, Moscow 119435, Russian Federation; avt420034{at}yahoo.com Gut microbiome ...